THE CHARACTERISTIC OF QUALITATIVE COMPOSITION OF THE MATRIX METALLOPROTEINASES IN HOMOGENATES OF TISSUES DURING THE DEVELOPMENT OF EXPERIMENTAL OBESITY IN THE RATS
DOI 10.17721/1728.2748.2022.88.51-55
Keywords:
obesity, metalloproteinases, enzymographyAbstract
Obesity is the complex and multifactorial disease that develops with influence of genetic, physiological, socio-economic and environmental factors. This disearse could increase the risk of comorbidities and mortality. Economic growth, automation of many technical processes and urbanization are the reasons of the sedentary lifestyle over the past 30 years, which has led to the widespreading of obesity among the population in 2 or even 4 times. In general, obesity is associated with excessive growth of adipose tissue, the development of which depends on cellular processes related to the population of cells such as adipocytes and their precursors. However, the accumulation of fat mass causes dysfunction of other tissues, which leads to a number of pathological processes. Our study was focused on the enzymatic activity of liver, kidney, and muscle tissue in obese rats. We have determined the changes the enzymatic activity matrix metalloproteinases (MMP) such as MMP-7 and MMP-9 in the experimental tissues. We found the manifestation of the enzymatic activity of MMP-7 in tissues of rats suffered with obesity, while in the healthy rats is not observed such the process. We suggest that this is due to the development of tissue fibrosis. An addition, we also recorded an increase in the enzymatic activity of MMP-9 in muscle tissue rats suffered with obesity. Probably, it links with the regenerative process in the experimental tissue. Further researches of the activity of matrix metalloproteinases in different tissues must provide knowledge about the biochemical processes during obesity which help to create the several right medicines and the development of new methods / approaches to the diagnostic and treatment of this pathology.
References
Upadhyay J, Farr, Perakakis, Ghaly W, Mantzoros C. Obesity as a Disease. Med Clin North. Am. 2018;102(1):13–33.
Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019 May;15(5):288-298. doi: 10.1038/s41574-019-0176-8.
Holvoet P. Stress in obesity and associated metabolic and cardiovascular disorders. Scientifica (Cairo). 2012;2012:205027. doi: 10.6064/2012/205027.
Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006 Dec 14;444(7121):875-80. doi: 10.1038/nature05487.
Shin YH, Kim KE, Lee YJ, Nam JH, Hong YM, Shin HJ. Associations of matrix metalloproteinase (MMP)-8, MMP-9, and their inhibitor, tissue inhibitor of metalloproteinase-1, with obesity-related biomarkers in apparently healthy adolescent boys. Korean J Pediatr. 2014 Dec;57(12):526-32. doi: 10.3345/kjp.2014.57.12.526.
Berg G, Barchuk M, Miksztowicz V. Behavior of Metalloproteinases in Adipose Tissue, Liver and Arterial Wall: An Update of Extracellular Matrix Remodeling. Cells. 2019 Feb 14;8(2):158. doi: 10.3390/cells8020158.
Yue B. Biology of the extracellular matrix: an overview. J Glaucoma. 2014 Oct-Nov;23(8 Suppl 1):S20-3. doi: 10.1097/IJG.0000000000000108.
Minematsu T, Huang L, Ibuki A, Nakagami G, Akase T, Sugama J, Nagase T, Yoshimura K, Sanada H. Altered expression of matrix metalloproteinases and their tissue inhibitors in matured rat adipocytes in vitro. Biol Res Nurs. 2012 Jul;14(3):242-9.
Derosa G. Matrix metalloproteinase-2 and -9 levels in obese patients / Derosa G., Ferrari I., D'Angelo A., Tinelli C. // Endothelium. – 2008. – Vol. 15. – P.219–224.
Ham M, Moon A. Inflammatory and microenvironmental factors involved in breast cancer progression. Arch Pharm Res. 2013 Dec;36(12):1419-31. doi: 10.1007/s12272-013-0271-7.
Belo VA, Lacchini R, Miranda JA, Lanna CM, Souza-Costa DC, Tanus-Santos JE. Increased activity of MMP-2 in hypertensive obese children is associated with hypoadiponectinemia. Obesity (Silver Spring). 2015 Jan;23(1):177-82. doi: 10.1002/oby.20939.
Souza MV, Leite RD, Souza Lino AD, Marqueti Rde C, Bernardes CF, Araújo HS, Bouskela E, Shiguemoto GE, Andrade Perez SE, Kraemer-Aguiar LG. Resistance training improves body composition and increases matrix metalloproteinase 2 activity in biceps and gastrocnemius muscles of diet-induced obese rats. Clinics (Sao Paulo). 2014;69(4):265-70. doi: 10.6061/clinics/2014(04)08.
Ostapchenko L, Savchuk O, Burlova-Vasilieva N. Enzyme electrophoresis method in analysis of active components of haemostasis system. Advances in Bioscience and Biotechnology. 2011;2: 20-26. doi: 10.4236/abb.2011.21004.
Lam S, Singh R, Dillman JR, Trout AT, Serai SD, Sharma D, Sheridan R, Su W, Fei L, Karns R, Haramija MM, Ridgway G, Goldfinger M, Squires JE, Denson LA, Hyams JS, Miethke AG. Serum Matrix Metalloproteinase 7 Is a Diagnostic Biomarker of Biliary Injury and Fibrosis in Pediatric Autoimmune Liver Disease. Hepatol Commun. 2020 Sep 24;4(11):1680-1693. doi: 10.1002/hep4.1589.
Irvine KM, Okano S, Patel PJ, Horsfall LU, Williams S, Russell A, Powell EE. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2021 Feb 3;11(1):2858. doi: 10.1038/s41598-021-82315-z.
Naim A, Pan Q, Baig MS. Matrix Metalloproteinases (MMPs) in Liver Diseases. J Clin Exp Hepatol. 2017 Dec;7(4):367-372. doi: 10.1016/j.jceh.2017.09.004.
Ke B, Fan C, Yang L, Fang X. Matrix Metalloproteinases-7 and Kidney Fibrosis. Front Physiol. 2017 Feb 10;8:21. doi: 10.3389/fphys.2017.00021.
Afkarian M, Zelnick LR, Ruzinski J, Kestenbaum B, Himmelfarb J, de Boer IH, Mehrotra R. Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. J Diabetes Complications. 2015 Nov-Dec;29(8):1024-31. doi: 10.1016/j.jdiacomp.2015.08.024.
Lo Presti R, Hopps E, Caimi G. Gelatinases and physical exercise: A systematic review of evidence from human studies. Medicine (Baltimore). 2017 Sep;96(37):e8072. doi: 10.1097/MD.0000000000008072.
